BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Spyre Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Spyre Therapeutics's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07012395-26@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SPY001: Phase 2 readout est. (NCT07012395)
DESCRIPTION:SPY001\, phase 2\, Ulcerative Colitis.\nStudy: A Study of Long-
 acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerat
 ive Colitis\nEstimated primary completion: June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/spy001#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07012395
URL:https://assetmemo.bio/drug/spy001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07766005-5971@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:SPY072: Phase 2 readout est. (NCT07766005)
DESCRIPTION:SPY072\, phase 2\, Hidradenitis Suppurativa.\nStudy: A Study of
  SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SK
 YLIGHT Trial)\nEstimated primary completion: October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/spy072#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07766005
URL:https://assetmemo.bio/drug/spy072#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652294-26@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290302
DTEND;VALUE=DATE:20290303
SUMMARY:SPY001: Phase 2 readout est. (NCT07652294)
DESCRIPTION:SPY001\, phase 2\, Ulcerative Colitis.\nStudy: Long-term Safety
  and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations
  for IBD\nEstimated primary completion: 2 March 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/spy001#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07652294
URL:https://assetmemo.bio/drug/spy001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
